Abstract
Both osteoporosis and hypertension are major diseases in aging populations. This work was provided to investigate the possible effect of the nonselective beta adrenoceptor antagonist; carvedilol against postmenopausal osteoporosis in adult rats. Ovariectomized rats were gavaged with carvedilol (10 mg/kg) daily for 60 days. Serum levels of estradiol, calcium and osteoblastic markers (alkaline phosphatase and osteocalcin) were measured. The bone resorbing cytokines (TNF-α and IL-6) were also evaluated. The oxidative stress markers were determined via measuring the lipid peroxidation product and the anti-oxidant markers in the serum. The bones were prepared for histomorphometric study. In comparison to the ovariectomized rats, carvedilol caused significant attenuation of the bone loss, biomechanical fragility, bone resorbing cytokines and oxidative stress. Current evidence suggests that administration of carvedilol has a beneficial effect on the bone quality in OVX rats via its antioxidant effect and attenuation of the bone resorbing cytokines.
Keywords: Beta blocker, carvedilol, IL-6, osteoporosis, oxidative stress, TNF-α.
Current Drug Therapy
Title:The Potential Effect of Carvedilol Against Osteoporosis in Ovariectomized Rats
Volume: 8 Issue: 3
Author(s): Vivian Boshra and Gehan Abdel Hamid El Wakeel
Affiliation:
Keywords: Beta blocker, carvedilol, IL-6, osteoporosis, oxidative stress, TNF-α.
Abstract: Both osteoporosis and hypertension are major diseases in aging populations. This work was provided to investigate the possible effect of the nonselective beta adrenoceptor antagonist; carvedilol against postmenopausal osteoporosis in adult rats. Ovariectomized rats were gavaged with carvedilol (10 mg/kg) daily for 60 days. Serum levels of estradiol, calcium and osteoblastic markers (alkaline phosphatase and osteocalcin) were measured. The bone resorbing cytokines (TNF-α and IL-6) were also evaluated. The oxidative stress markers were determined via measuring the lipid peroxidation product and the anti-oxidant markers in the serum. The bones were prepared for histomorphometric study. In comparison to the ovariectomized rats, carvedilol caused significant attenuation of the bone loss, biomechanical fragility, bone resorbing cytokines and oxidative stress. Current evidence suggests that administration of carvedilol has a beneficial effect on the bone quality in OVX rats via its antioxidant effect and attenuation of the bone resorbing cytokines.
Export Options
About this article
Cite this article as:
Boshra Vivian and Hamid El Wakeel Abdel Gehan, The Potential Effect of Carvedilol Against Osteoporosis in Ovariectomized Rats, Current Drug Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/15748855113086660010
DOI https://dx.doi.org/10.2174/15748855113086660010 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antithrombotic Options for Atrial Fibrillation in 2012
Cardiovascular & Hematological Disorders-Drug Targets Concerns and Hopes for Stem Cell Therapy in Cardiology: Focus on Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Current Alzheimer Research Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review
Current Vascular Pharmacology Endoplasmic Reticulum Stress and Atherosclerosis
Current Hypertension Reviews Medical Complications of Binge Eating Disorder
Current Women`s Health Reviews Genetic Basis of Renal Mass in Rat Models
Current Hypertension Reviews α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design Animal Models for Studying Neointima Formation
Current Vascular Pharmacology Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Current Pharmaceutical Design Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Understanding eNOS for Pharmacological Modulation of Endothelial Function: A Translational View
Current Pharmaceutical Design Linagliptin: A Novel Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor for Treatment of Type II Diabetes Mellitus
Current Diabetes Reviews 4-methylamphetamine (4-MA): Chemistry, Pharmacology and Toxicology of a New Potential Recreational Drug
Mini-Reviews in Medicinal Chemistry Lower Serum Indirect Bilirubin Levels are Inversely Related to Carotid Intima-Media Thickness Progression
Current Neurovascular Research Brain Inflammation Following Intracerebral Hemorrhage
Current Neuropharmacology Molecular Function of Tocopherols in Age Related Diseases
Current Pharmaceutical Design Progress and Prospects of Polyplex Nanomicelles for Plasmid DNA Delivery
Current Gene Therapy